Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aflatoxin B1 is a naturally occurring mycotoxin produced predominantly by the fungi Aspergillus flavus and Aspergillus parasiticus[4][5]. It is a colorless to pale yellow crystalline compound fluorescing blue under UV light and is considered the most toxic and carcinogenic aflatoxin, with a strong link to hepatocellular carcinoma (liver cancer) in humans and animals[1][3][4]. Aflatoxin B1 contaminates numerous crops (especially grains and nuts) in warm and humid climates, posing a major threat to food safety and public health worldwide. It is not a receptor, enzyme, transporter, or other classical drug/biological target, but rather itself a toxic small molecule of concern for poisoning and cancer risk[4][5][6].
Drugs do not act “on” Aflatoxin B1 as a therapeutic target; some therapies may: - Bind or degrade Aflatoxin B1 to reduce toxicity - Enhance its metabolic detoxification via hepatic enzymes (e.g., glutathione S-transferases) - Prevent its absorption in the gut using enterosorbents such as activated charcoal or cholestyramine
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aflatoxin B1 (AFB1).